Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation

Jack D. Stopa,1 Donna Neuberg,2 Maneka Puligandla,2 Bruce Furie,1 Robert Flaumenhaft,1 and Jeffrey I. Zwicker1

1Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center and Harvard Medical School, 
2Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.

BACKGROUND: Protein disulfide isomerase (PDI) is required for thrombus formation. We previously demonstrated that glycosylated quercetin flavonoids such as isoquercetin inhibit PDI activity and thrombus formation in animal models, but whether extracellular PDI represents a viable anticoagulant target in humans and how its inhibition affects blood coagulation remain unknown.

METHODS: We evaluated effects of oral administration of isoquercetin on platelet-dependent thrombin generation in healthy subjects and patients with persistently elevated anti-phospholipid antibodies.

RESULTS: Following oral administration of 1,000 mg isoquercetin to healthy adults, the measured peak plasma quercetin concentration (9.2 μM) exceeded its IC50 for inhibition of PDI by isoquercetin in vitro (2.5 ± 0.4 μM). Platelet-dependent thrombin generation decreased by 51% in the healthy volunteers compared with baseline (P = 0.0004) and by 64% in the anti-phospholipid antibody cohort (P = 0.015) following isoquercetin ingestion. To understand how PDI affects thrombin generation, we evaluated substrates of PDI identified using an unbiased mechanistic-based substrate trapping approach. These studies identified platelet factor V as a PDI substrate. Isoquercetin blocked both platelet factor Va and thrombin generation with an IC50 of ~5 μM.

Inhibition of PDI by isoquercetin ingestion resulted in a 53% decrease in the generation of platelet factor Va (P = 0.001). Isoquercetin-mediated inhibition was reversed with addition of exogenous factor Va.

CONCLUSION: These studies show that oral administration of isoquercetin inhibits PDI activity in plasma and diminishes platelet-dependent thrombin generation predominantly by blocking the generation of platelet factor Va. These pharmacodynamic and mechanistic observations represent an important step in the development of a novel class of antithrombotic agents targeting PDI.

TRIAL REGISTRATION: Clinicaltrials.gov (NCT01722669)

FUNDING: National Heart, Lung, and Blood Institute (US4 HL112302) and Quercegen Pharma

Role of funding source: NHLBI supported all aspects of study. Quercegen Pharma provided isoquercetin and funding support for pharmacokinetic analyses.

Authorship note: R. Flaumenhaft and J. I. Zwicker contributed equally to this work.

Conflict of interest: J. I. Zwicker received research support from Quercegen Pharma.

Submitted: July 11, 2016
Accepted: November 29, 2016
Published: January 12, 2017


Introduction

Protein disulfide isomerase (PDI) is a ubiquitously expressed thiol isomerase found in high concentrations in the endoplasmic reticulum (ER), where it serves an essential role in protein folding through disulfide bond shuffling. However, PDI can escape ER retention mechanisms in several cell types and localize to secretory granules and membrane surfaces. Within the vasculature, platelets and endothelial cells secrete PDI in the context of vascular injury or inflammation. Several animal models have demonstrated that extracellular PDI has a critical role in thrombus formation (1, 2). Inhibition of PDI by either monoclonal antibodies or small-molecule inhibitors prevents both platelet accumulation and fibrin formation at sites of vessel injury (2–4). Thrombus formation is also impaired in mice deficient in platelet PDI (5).

Flavonoid quercetins are among the small-molecule inhibitors of PDI that block thrombus formation. These flavonoids were first identified as PDI inhibitors in a high-throughput screen of an annotated library of known bioactive compounds that identified quercetin-3-rutinoside (also called rutin) as an inhibitor.
of PDI activity (6). Quercetin-3-rutinoside inhibited platelet aggregation and injury-induced fibrin formation on endothelium in cell-based assays. The administration of quercetin-3-rutinoside similarly inhibited thrombus formation following vascular injury in mouse models of thrombosis (6). Quercetin-3-rutinoside blocks PDI activity by binding to the substrate-binding pocket on PDI and inducing a conformational change in the enzyme, which results in a more compact molecular envelope and reduces substrate binding (7). Structure-activity relationship assays showed that all quercetins tested that possessed a glycoside at the third position on the C ring inhibited PDI, including isoquercetin (6) (also known as quercetin-3-glucoside), which has improved bioavailability in humans compared with quercetin-3-rutinoside (8–11). Interestingly, quercetins are flavonoids present in a wide variety of natural foods (e.g., fruits and vegetables), and a number of epidemiologic studies point to potential cardiovascular benefits of diets rich in quercetins. For instance, in the Zutphen Elderly study, high dietary consumption of quercetins was associated with a 70% decrease in mortality secondary to myocardial infarction (12). Consumption of quercetin has similarly been linked to a decrease in fatal and nonfatal cerebrovascular accidents (13).

Regulation of vascular cell surface receptors and coagulation proteins by modification of disulfide bonds represents a previously unrecognized layer of control of thrombus formation, akin to posttranslational modification by proteases. Unlike the role of proteases in blood coagulation, which has been studied in depth, little is known about the substrates and posttranslational modifications performed by PDI and other thiol isomerases. Several platelet and endothelial integrins such as Ibα (14), αIIbβ3 (15), and αVβ3 (16) are identified as putative substrates for PDI, but how PDI modifies these substrates is not well understood. Still less is known regarding which coagulation factors are directly targeted by extracellular PDI. A disulfide bond within factor XI can be reduced by PDI in vitro (17) and the Cys186-Cys209 disulfide bond in tissue factor may be susceptible to PDI-mediated thiol exchange, although this hypothesis remains controversial (18–21).

Following the discovery of a role for PDI in thrombus formation and the identification of quercetin-3-rutinoside as a small-molecule inhibitor of PDI activity with an established safety profile in humans, we initiated pharmacokinetic and pharmacodynamic clinical studies with quercetin analogs (quercetin aglycone and isoquercetin). Based on prior observations that PDI inhibition diminishes platelet-dependent thrombin generation in vitro, we mechanistically evaluated whether the oral administration of isoquercetin diminishes platelet-dependent generation of thrombin in humans in a PDI-dependent manner. Utilizing an unbiased strategy to identify novel substrates using PDI trapping variants (22), we now identify platelet factor V as a principal coagulation substrate of extracellular PDI. These studies provide therapeutic and mechanistic insights into a potentially novel class of antithrombotic drugs targeting PDI.

Results

Inhibition of PDI in human subjects using isoquercetin. Initial studies were designed to determine whether the oral administration of a quercetin flavonoid achieved plasma drug levels known to inhibit PDI activity in vitro (Figure 1). Accordingly, we evaluated whether the presence or absence of a glycoside moiety at the 3-C position of quercetin influenced absorption. We administered 500 mg quercetin aglycone or 500 mg isoquercetin orally to healthy adults. Venipuncture was performed prior to quercetin ingestion and then serially over 24 hours and total quercetin levels in plasma were measured. Quercetin aglycone (500 mg) ingestion yielded a median peak concentration (C_{max}) of 0.8 μM and an AUC of 3.8 μM hr/l (Figure 2A), whereas with 500 mg isoquercetin the C_{max} was 4.22 μM with an AUC of 18.3 μM hr/l (Figure 2B). Both quercetin analogs were formulated with ascorbic acid in order to prevent oxidation during storage. The addition of ascorbic acid did not influence the pharmacokinetic profile of either quercetin aglycone (AUC of 5.1 μM hr/l, Wilcoxon signed-rank test \( P = 0.31 \)) or isoquercetin (AUC of 13.6 μM hr/l, Wilcoxon signed-rank test \( P = 1.00 \)) (Figure 2). The highest isoquercetin dose we tested was 1,000 mg (\( n = 10 \)), which yielded a significantly higher peak plasma quercetin concentration (9.2 μM) and AUC (39.4 μM hr/l) compared with the isoquercetin 500-mg cohort (Mann-Whitney rank-sum test \( P = 0.03 \) for both variables) (Figure 2).

We developed a plasma-based assay to measure PDI inhibition following ingestion of flavonoids utilizing a fluorescence-based probe, di-eosin-GSSG, which consists of 2 eosin moieties coupled to glutathione disulfide (GSSG). Cleavage of di-eosin-GSSG by recombinant PDI results in liberation of the eosin moieties with a concomitant increase in fluorescence. As shown in Figure 2C, the ex vivo addition of quercetin-3-rutinoside, isoquercetin, or an abundant metabolite, quercetin-3-glucuronide, to plasma resulted in a dose-dependent inhibition of PDI activity in vitro. The IC_{50} for PDI inhibition was 2.5 ± 0.4 μM for isoquercetin, 8.5 ± 2.1 μM for quercetin-3-glucuronide, and 8.9 ± 2.3 μM for quercetin-3-rutinoside.
Using this PDI activity assay, we evaluated the pharmacodynamic inhibition of PDI activity over time by subjects who had ingested 1,000 mg isoquercetin. Inhibition of PDI activity mirrored the total quercetin concentrations in plasma (Figure 2D). We observed a significant 38% (95% CI 12.4% to 63%) reduction in PDI activity in subject plasmas by 2 hours following the administration of 1,000 mg isoquercetin compared with plasma obtained prior to isoquercetin ingestion ($P = 0.03$). In contrast, the ability of subject plasma to reduce PDI activity was not significantly changed 2 hours following ingestion of either 500 mg quercetin aglycone or 500 mg isoquercetin compared with plasmas obtained prior to flavonoid quercetin administration ($P = 0.98$ and $P = 0.68$, respectively). Accordingly, peak plasma quercetin concentration correlated with peak PDI inhibition (Spearman correlation coefficient 0.55, $P = 0.002$). At peak quercetin concentrations above 4 $\mu$M, the median inhibition of PDI was 0.69 U/ml compared with 0.29 U/ml for lower peak quercetin concentrations ($P = 0.002$, Figure 2E).

PDI inhibition using isoquercetin blocks thrombin generation. The platelet-dependent thrombin generation assay was designed to mimic thrombin propagation through platelet activation with low-dose thrombin (23). Increased platelet-dependent thrombin generation has been observed in hypercoagulable states (24, 25), and hemorrhagic conditions are associated with decreased activity (26, 27). In healthy individuals following 1,000 mg isoquercetin administration ($n = 10$), we observed a significant 51% reduction in thrombin generation at 4 hours (0.30 U/ml, 95% CI 0.09–0.50 U/ml) compared with baseline (0.59 U/ml, 95% CI 0.39–0.80 U/ml, $P = 0.0004$) (Figure 3B). Although no significant reduction in thrombin generation was observed in subject plasmas following a 500 mg dose of isoquercetin compared with baseline ($P = 0.22$), we observed a significant correlation between plasma quercetin levels and thrombin generation (Spearman correlation coefficient −0.34, $P = 0.02$). Plasma quercetin levels above 4 $\mu$M were associated with significantly lower platelet-dependent thrombin generation compared with plasma levels between 0 and 2 $\mu$M (Mann-Whitney $P = 0.012$).

To assess whether inhibition of endogenous PDI was responsible for the decrease in thrombin generation, we determined whether or not the effect of isoquercetin could be reversed by the inclusion of excess recombinant PDI in the reaction mixture. Healthy donor plasma was incubated with 10 $\mu$M isoquercetin ex vivo followed by exposure to 50 $\mu$M recombinant PDI. Inhibition of platelet-dependent thrombin generation by isoquercetin was reversed and thrombin generation normalized following incubation with excess PDI (Figure 3A). Similarly, the addition of 50 $\mu$M recombinant PDI to plasma from study subjects did not increase baseline thrombin generation (0.57 U/ml, 95% CI 0.43–0.72 U/ml) but restored thrombin generation at 4 hours following 1,000 mg isoquercetin ingestion (0.50 U/ml, 95% CI 0.34–0.66 U/ml, $P = 0.001$) to within 87% of baseline activity (Figure 3B). These results show that a molar excess of recombinant PDI is able to restore platelet-dependent thrombin generation following inhibition by isoquercetin, implicating PDI as the principal target of isoquercetin in this assay.

Prothrombin time (PT) was unaffected by the administration of isoquercetin, with a mean PT of 12.8 seconds (95% CI 12.4–13.2 seconds) at baseline compared with 12.8 seconds (95% CI 12.4–13.3 seconds) after 4 hours ($P = 0.82$). Similarly, thrombin times (TTs) were similar at baseline (16.8 seconds, 95% CI 15.7–17.9 seconds) and at 4 hours (16.3 seconds, 95% CI 14.7–17.9 seconds) following isoquercetin ingestion ($P = 0.46$).
Thrombin generation in patients with elevated anti-phospholipid antibodies. In order to evaluate the potential anticoagulant activity of isoquercetin in a patient population at increased risk for thrombosis, we evaluated thrombin generation in patients with persistently elevated anti-phospholipid antibodies who were not taking anticoagulants or antiplatelet agents (n = 6). In this cohort were 5 individuals with lupus anticoagulant and 1 patient with high-titer anti-cardiolipin IgM antibodies (above 100 IgG phospholipid [GPL]). As shown in Figure 4, baseline thrombin generation was significantly higher compared with healthy controls (P = 0.01). All 6 patients with anti-phospholipid antibodies had lower thrombin generation following 1,000 mg isoquercetin ingestion with a mean decrease of 63.6% in thrombin generation at 4 hours compared with baseline (4.01 U/ml vs. 1.46 U/ml, P = 0.015).

PDI inhibition decreases generation of platelet factor Va. We have previously developed an unbiased strategy to identify novel substrates of PDI in washed platelets using PDI variants capable of trapping substrates (22). This approach uses a FLAG-tagged PDI variant modified by a substitution of arginine or proline for histidine (CGHC → CGRC; CGHC → CGPC) in the catalytic motif of both the a and a’ domains. Although these variant PDIs remain capable of forming mixed disulfide bonds with putative substrate proteins, their ability to resolve the mixed disulfide bond is impaired and the duration of the PDI-substrate intermediate prolonged. This intermediate can be captured by alkylation of free thiols by N-ethylmaleimide (NEM) to prevent resolution of the mixed disulfide bond. The PDI-substrate complex is isolated using immobilized anti-FLAG antibody and subsequently identified by mass spectrometry. Using this strategy, we have now identified platelet factor V as a substrate of PDI (Figure 5).
was performed using both the PDI-CGPC and PDI-CGRC variants. To confirm that the interaction of PDI with platelet-derived factor V involves a disulfide modification and not noncovalent binding, we performed substrate trapping experiments using a FLAG-tagged PDI variant in which the catalytic cysteines in the $a$ and $a'$ domains were mutated to alanine (CGHC $\rightarrow$ AGHA). Washed platelets were stimulated with thrombin in the presence of FLAG-tagged PDI variants. The CGRC-PDI variant coprecipitated with platelet factor V, while there was no platelet factor V detected with the AGHA-PDI variant, thus confirming the direct binding of PDI with platelet-derived factor V by disulfide bond exchange (Figure 5A).

A special property of these variants compared with previously trapping strategies (28, 29) is that they are able to trap substrates regardless of whether they are reduced or oxidized by PDI. These mutants were prereduced or preoxidized to bias trapping of reduced substrates or oxidized substrates, respectively (22). A comparison of the ability of preoxidized versus prereduced forms of the mutants to trap a particular substrate provides an indication of whether PDI oxidizes or reduces the substrate. The amount of substrate trapped by the CGRC-PDI and CGPC-PDI variants are quantified by densitometry. The ratio of factor V trapped by the prereduced form of the variant compared with the preoxidized form of the variant (reduced/oxidized) was 2.88 for CGRC-PDI and 1.29 for CGPC. Thus, the trapping mutants were more effective following reduction than following oxidation, indicating that PDI reduces platelet factor V (Figure 5A). Evaluation of trapping experiments using agarose gels to identify high-molecular-weight complexes demonstrated that factor V from platelets is present in a high-molecular-weight complex with multimerin (Figure 5B).

To evaluate the effect of PDI inhibition on the activation of factor V, washed platelets from healthy donors were stimulated with 0.1 U/ml thrombin in the presence of varying concentrations of isoquercetin (0 to 50 μM). Platelet releasates were immunoblotted for factor Va. As shown in Figure 6, we observed a dose-dependent reduction in factor Va following platelet activation. The reduction in factor Va generation paralleled the reduction in thrombin generation in experiments performed under the same conditions (Figure 6B). PDI activity in the presence of isoquercetin decreased over the same concentrations of isoquercetin (Figure 6B). At 10 μM isoquercetin, no additional decrease in thrombin generation was observed when an inhibitory anti–factor Va antibody (280 μg/ml) was combined with isoquercetin (43.7% vs. 50.2%, $P = 0.66$), suggesting that complete platelet factor Va inhibition is achieved at this isoquercetin concentration. Platelet $\alpha$-granule release of platelet factor 4 (PF4) did not demonstrate a similar effect, arguing against the observed reduction in factor Va representing a decrease in platelet activation and impaired secretion in response to
thrombin (Figure 6C). In the absence of platelets, isoquercetin (10 μM) did not directly inhibit factor Xa or prothrombinase complex activity (Figure 6, D and E).

In order to determine whether the effect of isoquercetin on factor Va generation contributes to its inhibition of thrombin generation in human subjects, we analyzed patient plasma following the oral consumption of isoquercetin. Plasma samples collected from healthy participants before and 4 hours after ingestion of 1,000 mg of isoquercetin (n = 17) were immunodepleted of factor V. Factor V–depleted plasma was reconstituted with healthy donor platelets and stimulated with low-dose thrombin. Platelet stimulation using factor V–depleted plasma yielded 45% less measured factor Va relative to non–factor V–depleted plasma (P < 0.001). Thus, in these experiments approximately 55% of factor Va in plasma following platelet activation is derived from platelet stores. Following the oral administration of isoquercetin, we observed an overall 26% reduction in factor Va in non–factor Va–depleted plasma (P < 0.001), which corresponded with a 53% decrease in factor Va generated from platelets (P < 0.001, Figure 7, A and B). These data confirm a significant effect of isoquercetin ingestion on the generation of factor Va following platelet activation. Considering that isoquercetin reduces platelet factor Va generation and similarly inhibits platelet-dependent thrombin generation in a PDI-dependent manner, we investigated whether the addition of factor Va in vitro restored platelet-dependent thrombin generation. The preincubation of 7 μg/ml factor Va prior to stimulation with low-dose thrombin significantly increased platelet-dependent thrombin generation (P = 0.04) to within 80% baseline of pretreatment levels (Figure 7C). We conclude that isoquercetin-mediated inhibition of PDI activity significantly decreases platelet-dependent thrombin generation predominantly through a reduction in platelet-derived factor Va generation.

**Discussion**

Although PDI is primarily a resident protein of the ER and dense tubular system in endothelial cells and platelets, respectively, a small portion of PDI resides in granules and is released upon cell activation. This extracellular PDI serves an essential role in thrombus formation in vivo (2–4). The fortuitous observation that certain quercetin flavonoids inhibit PDI facilitated the investigation of extracellular PDI as a druggable antithrombotic target in humans (6). To the best of our knowledge, we report the first clinical study specifically designed to target extracellular PDI in humans.

Quercetin-3-rutinoside was the most potent small-molecule inhibitor of PDI identified in a high-throughput screen of biologically active compounds (6). Quercetin-3-rutinoside administered intravenously to mice abolished both platelet accumulation and fibrin generation at the site of a vascular injury, an effect that reversed completely following administration of recombinant PDI (6). Quercetin-3-rutinoside binds reversibly to the b' domain of PDI, leading to a conformational change that is detected by small-angle x-ray scattering as a reduction in the molecular envelope (7). Structure-activity relationship studies identified several quercetin analogs with similar anti-PDI activity including isoquercetin. All quercetin flavonoid analogs assayed that contained a glycoside at the 3-C position of the quercetin backbone demonstrated anti-PDI activity (6). This
same glycoside that is required for the anti-PDI activity also impairs the ability of quercetin flavonoids to permeate cell membranes, thereby targeting extracellular PDI. Although the antithrombotic activity of quercetin-3-rutinoside was initially tested in animal models, its absorption in humans is known to be poor (8, 30). We performed a comparative pharmacokinetic study between quercetin aglycone and isoquercetin and observed that oral administration of 1,000 mg isoquercetin achieves plasma concentrations in line with the IC50 derived from PDI inhibitory assays in vitro (6). We confirmed on-target activity, as plasma obtained following administration of isoquercetin significantly reduced PDI activity in a time- and concentration-dependent manner.

**Figure 5. Factor V is a substrate of protein disulfide isomerase (PDI).** (A) PDI trapping mutants react with factor V released from activated platelets. PDI variants (CGPC-PDI, CGRC-PDI, or AGHA-PDI) labeled with an N-terminal FLAG tag were either prereduced (Reduced) or preoxidized (Oxidized) prior to incubation with platelets. Washed platelets were stimulated with thrombin in the presence of 1 of the FLAG-tagged PDI variants. Platelets were separated from releasates by centrifugation and FLAG-tagged PDI constructs were pulled down using anti-FLAG antibody–coated beads. Precipitated proteins were resolved by polyacrylamide gel electrophoresis under nonreducing conditions, transferred to PVDF, and immunobotted (IB) for both FLAG (green) and factor V (red). Overlapping bands are shown in yellow in the merge. (B) Evaluation of nonreduced samples indicates that factor V (FV) trapped by PDI variants associates with multimerin-1 (MMN-1). Pulldowns of PDI variants (CGPC-PDI, CGRC-PDI, or AGHA-PDI) were performed as described in A. Samples were resolved under nonreducing conditions using agarose electrophoresis to resolve high-molecular-weight complexes and transferred to PVDF membranes. Membranes were subsequently stained using anti-FV antibody (anti-FV) and anti-MMN1 antibody (anti-MMN1). For all panels, representative images are shown for experiments performed in triplicate.
In order to evaluate the potential anticoagulant activity of PDI inhibition in humans, we measured thrombin generation in a coagulation assay dependent on PDI activity on the thrombin-platelet amplification loop (31). Following oral administration of isoquercetin, platelet-dependent thrombin generation in plasma decreased significantly in both the healthy cohort as well as in individuals with anti-phospholipid antibodies. The addition of recombinant PDI to the posttreatment plasma samples significantly increased thrombin generation, thus confirming the PDI-dependent nature of the observed isoquercetin-mediated decrease in thrombin generation. The marked inhibition in thrombin generation observed in patients with anti-phospholipid antibodies (and high baseline thrombin generation) is intriguing considering the heightened risk for arterial and venous thrombosis without a validated approach for primary prevention. We observed an approximately 90% normalization of thrombin generation with the addition of exogenous PDI to isoquercetin-treated plasma, thus indicating a small contribution for off-target anticoagulant activity of the drug. Our group is working to identify and characterize more specific small-molecule inhibitors of
PDI, which may enable a more targeted investigation of the thrombotic mechanisms under regulatory control of PDI in vivo (32, 33).

PDI activity has previously been shown to influence platelet-dependent thrombin generation, which we now show is dependent on PDI-mediated activation of platelet factor V. Although platelet-derived factor Va only accounts for 20% of the total amount of factor V measured in plasma, this pool plays a critical role in supporting hemostasis. Thrombin generation in the presence of normal platelets does not require plasma factor V and endogenous thrombin potential is not significantly reduced in patients with congenital factor V deficiency (absent plasma factor Va but measurable platelet factor Va) (34). In our experiments using human plasma depleted of factor V, we observed an approximately 75% reduction in platelet-generated factor Va following isoquercetin ingestion. This reduction in platelet factor Va generation paralleled inhibition of PDI. The significant decrease in generation of factor Va following isoquercetin exposure was not due to decreased platelet activation, direct alteration of prothrombin or factor Xa, or the direct inhibition of thrombin or factor Xa.

The precise mechanism by which PDI influences the generation of platelet-dependent factor Va has yet to be elucidated. Factor V contains 18 cysteine residues: 14 form intramolecular disulfide bridges and 4 are unpaired, free sulfhydryl groups, 2 of which are readily accessible (35). Modification of free sulfhydryls within factor Va does not alter the rate of prothrombin activation (36). Factor V is stored within platelet α-granules in complex with multimerin partially through disulfide linkages (37). Multimerin-1 in complex with factor V inhibits thrombin generation (38). Further studies, however, are necessary to determine whether PDI mediates the release of factor V/Va from multimerin following platelet activation. Although the generation of platelet-derived factor Va appears to be the dominant driver in the PDI-mediated reduction in platelet-dependent thrombin generation, evidence points against this being the only PDI substrate influencing thrombin generation in this assay. PDI-mediated activation of platelet integrins such as GPIb and αIIbβ3 integrin or other coagulation targets (22) may explain the observation that restoration of thrombin generation by incubation with exogenous factor Va was incomplete, achieving 85% of baseline levels (Figure 7C). Furthermore, thrombus formation in vivo is considerably more complex than the platelet-dependent thrombin generation assay, which we use as a convenient functional measure of anti-PDI activity in human subjects. PDI substrates on endothelium and leukocytes could also contribute...
to thrombus formation in vivo. Surface receptors and adhesion proteins may serve more prominent roles under flow conditions. Nonetheless, the finding that PDI inhibition blocks platelet-dependent thrombin generation in human subjects provides what we believe to be the first mechanistic evidence of how PDI inhibition could impair thrombosis in human studies.

Despite an expanding list of antithrombotics available for therapeutic use, thrombotic disease remains the leading cause of mortality in developed countries. PDI inhibitors represent a novel multitarget anticoagulant that inhibits both platelet aggregation and fibrin generation with the potential to impact the management of complex thrombotic disorders such as myocardial infarction and cancer-associated thrombosis. There is considerable epidemiologic evidence linking quercetin-rich diets and improved cardiovascular outcomes. For instance, in a large prospective study of approximately 100,000 adults in the United States, the highest quintile of flavonoid consumption was associated with an approximately 20% decrease in cardiovascular deaths (adjusted risk ratio 0.82, 95% CI 0.73–0.92, P = 0.01) (39). This report of pharmacodynamic inhibition of PDI with isoquercetin along with underlying mechanistic studies identifying platelet factor Va as a dominant anticoagulant substrate of PDI represents an important first step in the development of a novel class of antithrombotic agents targeting PDI. Based on these data we initiated advanced-stage clinical trials to assess the efficacy of isoquercetin to prevent thrombosis in high-risk cancer patients (NCT02195232).

**Methods**

**Eligibility.** Enrollment into the healthy cohort only included participants without known liver, kidney, cardiac, or other chronic illness. Participants were excluded if taking anticoagulants or antiplatelet agents (including nonsteroidal antiinflammatory medications). Study subjects were instructed to avoid quercetin-rich foods for 72 hours prior to administration of study drug. A flavonoid-free lunch was provided at 4 hours after the initial blood draw. Study subjects were allowed to participate in more than 1 cohort following a minimum of a 2-week washout period. For enrollment into the cohort with anti-phospholipid antibodies, study subjects were required to have at least 1 positive anti-phospholipid antibody assay (lupus anticoagulant, anticardiolipin antibody IgM or IgG > 40 GPL, or anti–β2 glycoprotein-1 antibody titer > 35 units) confirmed at least 8 weeks apart.

**Study procedures.** Quercetin aglycone and isoquercetin were provided by Quercegen Pharma. The cohorts including healthy subjects were: (a) 500 mg quercetin aglycone (n = 5); (b) 500 mg quercetin aglycone with 500 mg ascorbic acid and 20 mg niacin (n = 5); (c) 500 mg isoquercetin (n = 5); (d) 500 mg isoquercetin with 500 mg ascorbic acid and 20 mg niacin (n = 5); and (e) 1,000 mg isoquercetin with 1,000 mg ascorbic acid and 40 mg niacin (n = 10). Study subjects with anti-phospholipid antibodies received 1,000 mg isoquercetin with 1,000 mg ascorbic acid and 40 mg niacin (n = 6). For the healthy cohorts (a–e), blood was drawn prior to the administration of study drug and at 8 time points over a 24-hour period (0, 0.5, 1, 2, 4, 6, 8, and 24 hours). For patients with anti-phospholipid antibodies, blood was drawn at 0 and 4 hours only. Total plasma quercetin was measured by David Nieman at North Carolina Research Campus by previously described methods (40).

**Di-eosin-GSSG Assay.** Preparation of di-eosin-GSSG was performed as described (41). The platelet-poor plasma was filtered through a Millipore 30-kDa cutoff filter at 14,000 g and the filtrate incubated with 10 μM GSSG for 20 minutes at room temperature. Human recombinant PDI dual tagged with FLAG and streptavidin-binding peptide was expressed and isolated from *E. coli* (BL21) by affinity chromatography with streptavidin-linked agarose resin. Purified recombinant PDI was added at varying concentrations (0, 50, 100, and 250 nM) to filtered GSSG-treated plasma with 5 μM DTT and 150 nM di-eosin-GSSG. Enzymatic activity was monitored through the fluorescence of eosin (EGSH), which was excited at 525 nm and emission was recorded at 545 nm. Linear rates were obtained and converted to units of enzymatic activity per ml of PDI stock. Once standardized, 2 U/ml PDI was added to 5 μM DTT and 150 nM di-eosin-GSSG in a total volume of 80 μl with GSSG-treated filtered plasma. Percentage inhibition was assessed by the difference in measured units of activity from those of the standard. For the IC50 determination, 100 μM recombinant PDI was incubated in GSSG-treated filtered plasma for 5 minutes with concentrations of quercetin analog ranging from 20 nM to 3 mM in GSSG-treated filtered plasma and then assayed for enzymatic activity as described. Percentage inhibition was normalized to the no-addition control (100%).

**Thrombin generation.** Whole blood was drawn from volunteers just before (0 hours) and 4 hours after oral ingestion of 1,000 mg isoquercetin. Whole blood was spun at 300 g for 20 minutes to isolate platelet-rich
plasma (PRP). Platelet-free plasma (PFP) was generated by centrifuging PRP twice at 2,800 g for 10 minutes. PRP was diluted to a platelet concentration of 250,000 platelets per microliter with platelet-poor plasma in the presence of 5 mM Gly-Pro-Arg-Pro peptide (Thermo Fisher) and 6 mM CaCl₂, and then stimulated with 0.1 U/ml thrombin. For the thrombin generation rescue experiments, 50 μM PDI was also added. PRP samples were incubated for 90 minutes at room temperature with rotation, and thrombin levels were measured using cleavage of a fluorescent thrombin-specific substrate (Haemtech SN-20 Boc-L-FPR-ANSNH-C2H5) by excitation at 352 nm and emission as a function of time at 470 nm. PRP was diluted 1:4 into 1× PBS containing 100 μM fluorescent substrate and 12.5 mM EDTA. Rates of substrate cleavage were used to calculate the concentration of thrombin in each sample at time zero and 4 hours after isoquercetin ingestion.

**PDI variant generation and platelet factor V trapping.** The PDI gene (PDLA1) was inserted into the pT7-FLAG-SBP-1 vector purchased from Sigma-Aldrich. Point mutations in the PDI sequence were made in subsequent rounds using the Site-Directed Mutagenesis Quick Change Kit available from New England Biolabs as previously described (22). PDI protein was expressed in the BL21 strain of *E. coli*, first grown in LB media at 37°C until induced at 25°C with 1 mM isopropyl β-D-1-thiogalactopyranoside. Cells were lysed using the BPER Bacterial Protein Extraction Kit from Thermo Fisher. Clarified lysates were incubated with high-capacity streptavidin-coated agarose beads overnight at 4°C, washed with at least 10 column volumes of 1× Tris-buffered saline with 0.1% Tween-20 (TBST), and eluted with 2 mM biotin in TBST. Eluates were dialyzed 3 times against 1× PBS, concentrated, and stored frozen at -80°C.

Purified PDI variants or inactive PDI were added to washed platelets (1 × 10⁹ to 3 × 10⁹) in the presence or absence of 1 mM CaCl₂, 10 mM MnCl₂, and 1.0 U/ml thrombin and allowed to incubate at room temperature for 3 minutes. Hirudin (20 U/ml) was added and incubated for 1 minute. NEM (20 mM) was added and allowed to incubate at room temperature protected from light for 30 minutes. The platelet suspension was then spun down at 1,000 g for 10 minutes and separated into releasate and pellet fractions. The releasate fraction was spun for an additional 5 minutes at 2,800 g. The pellet fraction was resuspended in 1 ml of cold 20 mM Tris (pH 7.4), 2% Triton X-100, 20 mM EGTA, 20 mM MgCl₂, 2 mM ATP, 20 mM NEM, 0.025 mg/ml cytochalasin D, 0.8 mM PMSF, and 1× Protein Inhibitor Cocktail (Thermo Fisher), and incubated on ice for 30 minutes with regular inversion. The platelet lysate was then mixed with 1 ml cold 2 M Tris (pH 7.0), 0.5 mM ATP, 0.2 mM MgCl₂, and 20 mM NEM, and incubated on ice for 30 minutes with regular inversion. The lysate was then centrifuged at 13,100 g for 10 minutes at 4°C. PDI-substrate complexes were captured from clarified lysates or releasates using anti-FLAG magnetic beads (M2 monoclonal, Sigma-Aldrich) by inversion overnight at 4°C in the dark. The magnetic beads were separated and rinsed 3 times with 20 mM HEPES (pH 7.4), 5% Triton X-100, and 500 mM NaCl. Complexes were eluted by heating at 95°C for 15 minutes in Laemmli buffer.

**Antibodies.** All primary antibodies were directed toward human antigens except for FLAG antibodies. All antibodies were used at manufacturer-recommended dilutions unless otherwise stated. For immunoprecipitation of FLAG-tagged species, mouse anti-FLAG M2 monoclonal (Sigma-Aldrich, M8823) was used. For identification of FLAG-tagged species during trapping experiments, rabbit anti-FLAG (Abcam, ab1162) was used. For identification of factor V during trapping experiments, sheep anti–factor V polyclonal (Thermo Fisher, PAI-43041) was used. For identification of multimerin-1 (MMN1) during trapping experiments, mouse anti-MMN1 monoclonal, JS1, a gift from Catherine Hayward (McMaster University, Ontario, Canada) was used. For immunoprecipitation of factor V from plasma, we used mouse anti–factor V monoclonal (Haematologic Technologies, AHV-5146). For identification of factor Va via Western blot, mouse anti–factor Va monoclonal (Haematologic Technologies, AHV-5112) was used. For inhibition of factor V during thrombin generation, we used a mouse anti–factor V monoclonal (Haematologic Technologies, AHV-5101).

**Clotting assays.** All PT and TT assays were performed on a Stago Start 4 instrument using the manufacturer's standard protocol and STA Neoplastin CI Plus (Stago).

**Measuring factor Xa activity.** Purified factor Xa (Haemtech) was diluted to 10 μg/ml in PBS along with 7 μg/ml factor Va in the presence or absence of isoquercetin (10 μM) and assayed for activity against either a synthetic factor Xa cleavage substrate (Haemtech, SN-7), or purified prothrombin (Haemtech). For assaying activity against prothrombin, 50 μg/ml prothrombin was incubated with factor Xa, and then the solution was assayed for thrombin activity using a synthetic thrombin cleavage substrate (Haemtech, SN-20). Cleavage of both substrates was monitored over time via fluorescence, exciting at 352 nm and measuring emission over time at 470 nm in a Synergy 4 Fluorescent Plate Reader (BioTek).
Statistics. Pharmacokinetic analysis was performed using STATA software. Statistical comparisons for intra-dosing cohorts (e.g., quercetin with or without ascorbic acid) were performed using a paired nonparametric analysis (Wilcoxon signed-rank test) for the AUC and C_{\text{max}}. Comparisons between baseline and subsequent measurement of PDI activity and thrombin generation were performed using 2-tailed, paired t-test analysis. Statistical significance was defined as a P value less than 0.05. ANOVA with Sheffe’s correction for multiplicity testing was performed for PDI and factor V rescue experiments.

Study approval. The protocol was approved by the IRB at Beth Israel Deaconess Medical Center. All study subjects provided written informed consent prior to the initiation of study procedures.

Author contributions
JDS designed and conducted experiments, acquired data, analyzed data, and contributed to writing of the manuscript. DN and MP performed statistical analyses. BF conceived of substrate trapping experiments, contributed to writing of the manuscript, and edited the manuscript. RF and JIZ conceived of pharmacokinetic and pharmacodynamics studies, wrote the manuscript, and edited the manuscript. JIZ designed clinical studies.

Acknowledgments
This work was supported by a grant from the National Heart, Lung, and Blood Institute (U54 HL112302, HL007917, and HL125275) as well as research support from Quercegen Pharma. Research in patients with anti-phospholipid antibodies was supported, in part, by the Lupus Research Institute. Clinical research support was provided in part by the Harvard Catalyst, the Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH award 8UL1TR000170-05 and financial contributions from Harvard University and its affiliated academic health care centers). Anti–multimerin-1 antibody was a gift from the Hayward group (McMaster University, Ontario, Canada). The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the NIH.

Address correspondence to: Jeffrey I. Zwicker or Robert Flaumenhaft, Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215, USA. Phone: 617.667.9299; E-mail: jzwicker@bidmc.harvard.edu (J.I. Zwicker). Phone: 617.735.4001; E-mail: rflaumen@bidmc.harvard.edu (R. Flaumenhaft).


